Diamonds in the Rough
Cross-referencing fundamental value against technical exhaustion to isolate beaten-down XBI constituents that screen cheap and oversold. The bottom-right quadrant — high earnings yield, low RSI — is the prime hunting ground, especially where money flow (MFI) shows quiet accumulation despite the falling price.
Educational screen, not investment advice. “Diamond” classification is a mechanical valuation-vs-RSI split around the cohort median earnings yield and an RSI of 50.
Alpha Quadrant — Valuation × Technical Exhaustion
X = earnings yield (cheaper right) · Y = RSI 14 (more oversold lower) · bubble = market cap · color = money flow.
Diamond Candidates
Ranked by a composite of earnings yield, ROIC, oversold RSI, recent weakness, and improving money flow.
| # | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | IRWD | Ironwood Pharmaceuticals, Inc. - Class A | 85.6 | 25.81% | 1.38 | 34 | -15.55% | 59 | distress |
| 2 | ABUS | Arbutus Biopharma Corporation Common Stock | 70.5 | 17.21% | 0.55 | 28 | -12.75% | 30 | safe |
| 3 | INCY | Incyte Genomics Inc | 67.1 | 9.16% | 0.33 | 34 | -8.80% | 25 | safe |
| 4 | NBIX | Neurocrine Biosciences Inc | 58.8 | 5.39% | 0.90 | 41 | -9.03% | 38 | safe |
| 5 | REGN | Regeneron Pharmaceuticals Inc | 57.9 | 5.05% | 0.21 | 35 | -11.02% | 46 | safe |
| 6 | RIGL | Rigel Pharmaceuticals Inc. (New) | 56.1 | 10.13% | 0.97 | 52 | -1.77% | 59 | safe |
| 7 | AMGN | Amgen Inc | 54.1 | 4.37% | 0.63 | 48 | -8.54% | 71 | safe |
| 8 | EXEL | Exelixis Inc | 54.1 | 6.85% | 0.99 | 56 | +2.06% | 77 | safe |
| 9 | ADMA | ADMA Biologics, Inc. | 50.5 | 9.68% | 0.42 | 53 | +4.07% | 65 | safe |
| 10 | ALNY | Alnylam Pharmaceuticals, Inc. | 50.1 | 3.48% | 0.27 | 34 | -10.86% | 32 | safe |
| 11 | VRTX | Vertex Pharmaceuticals Inc | 48.9 | 3.92% | 0.47 | 39 | -8.63% | 41 | safe |
| 12 | ANAB | AnaptysBio, Inc. Common Stock | 48.4 | 3.39% | 0.15 | 28 | -13.54% | 33 | grey |
| 13 | ACAD | Acadia Pharmaceuticals Inc. | 45.1 | 2.83% | 0.10 | 16 | -31.44% | 14 | safe |
| 14 | HALO | Halozyme Therapeutics, Inc. | 43.8 | 4.47% | 0.96 | 53 | +3.80% | 73 | safe |
| 15 | KRYS | Krystal Biotech, Inc. Common Stock | 41.1 | 2.17% | 0.18 | 37 | -11.95% | 17 | safe |
Short-Squeeze Watch
Constituents with the highest composite squeeze score — heavy short interest meeting price support.
| # | |||||||
|---|---|---|---|---|---|---|---|
| 1 | IBRX | ImmunityBio, Inc. Common Stock | 98.3 | 31.75% | 15.86 | +29.45% | critical |
| 2 | ZBIO | Zenas BioPharma, Inc. Common Stock | 91.9 | 38.10% | 22.43 | -12.15% | critical |
| 3 | ABSI | Absci Corporation Common Stock | 90.2 | 31.21% | 14.44 | +24.38% | critical |
| 4 | KOD | Kodiak Sciences Inc Common Stock | 89.4 | 34.19% | 17.87 | +152.27% | critical |
| 5 | PGEN | Precigen, Inc. Common Stock | 86.0 | 23.77% | 16.27 | +23.59% | critical |
| 6 | SPRY | ARS Pharmaceuticals, Inc. Common Stock | 85.9 | 47.10% | 15.51 | -30.55% | critical |
| 7 | PRME | Prime Medicine, Inc. Common Stock | 84.7 | 33.59% | 12.31 | -14.86% | critical |
| 8 | RLAY | Relay Therapeutics, Inc. Common Stock | 84.3 | 28.23% | 14.22 | +1.39% | critical |
| 9 | COAG | Hemab Therapeutics Holdings, Inc. Common Stock | 83.8 | 41.73% | 7.54 | -30.11% | critical |
| 10 | SMMT | Summit Therapeutics Inc. Common Stock | 83.6 | 29.87% | 6.56 | +18.41% | critical |
| 11 | NGNE | Neurogene, Inc. Common Stock | 82.7 | 25.48% | 16.85 | -32.45% | critical |
| 12 | OLMA | Olema Pharmaceuticals, Inc. Common Stock | 82.3 | 27.84% | 15.93 | -22.26% | critical |
Market cap, valuation, and short-interest metrics are joined to the latest XBI holdings snapshot; each ticker links to its full quote and analysis page.